Barinthus Biotherapeutics Stock (NASDAQ:BRNS), Quotes and News Summary

Q: What sector and industry does Barinthus Biotherapeutics (BRNS) operate in?

Barinthus Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Barinthus Biotherapeutics Stock (NASDAQ: BRNS) stock price, news, charts, stock research, profile.

Open	$2.400
Close	$2.500
Volume / Avg.	6.864K / 22.085K
Day Range	2.400 - 2.600
52 Wk Range	2.170 - 5.000
Market Cap	$104.309M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	44
Short Interest	0.04%
Days to Cover	1

Recent News

Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.

Vandana Singh

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates

Synlogic, Inc. (NASDAQ: SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trend

Nov 23

Mar

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About Barinthus Biotherapeutics Plc.

Sector

Health Care

Industry

Biotechnology

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Barinthus Biotherapeutics (BRNS) stock?

You can purchase shares of Barinthus Biotherapeutics (NASDAQ: BRNS) through any online brokerage.

View our list of the best stock brokerages.

Who are Barinthus Biotherapeutics's (BRNS) competitors?

Other companies in Barinthus Biotherapeutics’s space includes: Anixa Biosciences (NASDAQ:ANIX), CytomX Therapeutics (NASDAQ:CTMX), Curis (NASDAQ:CRIS), Cellectar Biosciences (NASDAQ:CLRB) and Burning Rock Biotech (NASDAQ:BNR).

What is the target price for Barinthus Biotherapeutics (BRNS) stock?

The latest price target for Barinthus Biotherapeutics (NASDAQ: BRNS) was reported by HC Wainwright & Co. on Monday, April 22, 2024. The analyst firm set a price target for 8.00 expecting BRNS to rise to within 12 months (a possible 198.51% upside). 4 analyst firms have reported ratings in the last year.

Current Stock Price for Barinthus Biotherapeutics (BRNS)?

The stock price for Barinthus Biotherapeutics (NASDAQ: BRNS) is $2.68 last updated April 25, 2024 at 2:05 AM EDT.

Does Barinthus Biotherapeutics (BRNS) pay a dividend?

There are no upcoming dividends for Barinthus Biotherapeutics.

When is Barinthus Biotherapeutics (NASDAQ:BRNS) reporting earnings?

Barinthus Biotherapeutics’s Q1 earnings are confirmed for Friday, May 10, 2024.

Is Barinthus Biotherapeutics (BRNS) going to split?

There is no upcoming split for Barinthus Biotherapeutics.

What sector and industry does Barinthus Biotherapeutics (BRNS) operate in?

Barinthus Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-